Protein Engineering News and Research

RSS

NPI leaders to invest more than $30M to support White House BRAIN Initiative

Leaders of the National Photonics Initiative (NPI), an alliance of top scientific societies uniting industry and academia to raise awareness of photonics, launched its Photonics Industry Neuroscience Group alongside officials from the White House Office of Science and Technology (OSTP) in conjunction with today's White House BRAIN Initiative conference.

30 Sep 2014

Researchers develop protein therapy that may stop cancer growth

A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.

22 Sep 2014

Zebrafish may hold key to unlocking a leading cause of respiratory diseases

A small freshwater fish found in many tropical aquariums may hold the key to unlocking one of the leading causes of respiratory diseases in humans.

17 Sep 2014

A*STAR scientists pioneered a molecular connection between obesity and diabetes

Scientists from the Institute of Molecular and Cell Biology, a research institute under the Agency for Science, Technology and Research, have discovered that obese individuals lack a protein that is essential for regulating blood glucose levels, causing them to face higher risks of developing diabetes.

1 Jul 2014

UK's TSB provides £347,000 for project to optimise gene library assembly technology

Today, Monday 30th June, 2014, Isogenica, Cambridge UK and Imperial College London secure funding from the Technology Strategy Board (TSB), the UK's innovation agency, for a £347,000 project to optimise a gene library assembly technology for potential use in synthetic biology.

30 Jun 2014

Scientists develop new molecule for monitoring drug concentration

Monitoring the drug concentration in patients is critical for effective treatment, especially in cases of cancer, heart disease, epilepsy and immunosuppression after organ transplants.

9 Jun 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results and operational highlights for the quarter ended March 31, 2014.

15 May 2014

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China.

10 Apr 2014

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

27 Mar 2014

Scientists build tiny "molecular drill bits" that kill bacteria by bursting through their protective cell walls

In response to drug-resistant "superbugs" that send millions of people to hospitals around the world, scientists are building tiny, "molecular drill bits" that kill bacteria by bursting through their protective cell walls.

18 Mar 2014

Novimmune closes Series B financing for CHF 60 million

Novimmune SA announced that it has closed a Series B financing for CHF 60 million ($66 million). London-based Rosetta Capital Limited led the round with participation of new private investors as well as existing investors.

18 Feb 2014

University of Liège joins IMI programme to develop new antibiotics against Gram-negative pathogens

More than 30 European universities and companies, led by GlaxoSmithKline, are joining forces in a six-year programme funded by the Innovative Medicines Initiative (IMI) for the sum of EUR 85 millions with the aim of developing new antibiotics against Gram-negative pathogens.

14 Feb 2014

Llama-derived antibodies open door to development of new treatments for C. difficile infections

Researchers from the Alberta Glycomics Centre at the University of Calgary and the University of Alberta, in collaboration with researchers at the National Research Council of Canada in Ottawa, have revealed the first molecular views showing how highly specific antibodies derived from llamas may provide a new method for controlling deadly infections from the opportunistic bacterial pathogen Clostridium difficile (C. difficile).

31 Jan 2014

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier (BBB) into the brain in preclinical models.

10 Jan 2014

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

Although drugs have been developed that inhibit the imbalance of neurotransmitters in the brain - a condition which causes many brain disorders and nervous system diseases - the exact understanding of the mechanism by which these drugs work has not yet been fully understood.

8 Jan 2014

Study quantifies photoactivation efficiency of fluorescent proteins

To know how many proteins assemble together at the nanoscale is fundamental for understanding protein function. Sometimes, proteins must be in an "oligomeric" state to be functional, although "oligomerization" of certain proteins can also lead to diseases. The ability to determine protein stoichiometry and monitor changes in the balance between monomeric, dimeric and multi-meric proteins can allow scientists to see the differences between a properly functioning cell and a diseased cell. Therefore, there is a great interest in being able to count proteins and determine their stoichiometry.

7 Jan 2014

MedImmune, Johns Hopkins University enter into $6.5M research collaboration

MedImmune, AstraZeneca’s global biologics research and development arm, and The Johns Hopkins University today announced they have entered into a five-year, $6.5 million research collaboration.

12 Dec 2013

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

2 Dec 2013

EU-funded project develops new type of vaccine to tackle HIV virus infection

AIDS research has attempted many strategies to tackle the HIV virus infection. Now, a new type of vaccine developed within an EU-funded project, called EuroNeut-41, is based on one of the envelope proteins of the HIV virus, called the gp41 protein. What makes it interesting it that it is directly responsible for the fusion of the HIV virus into human cells. By integrating the gp41 protein into the vaccine, researchers try to trigger the production of antibodies that would block the entrance of HIV into human cells

27 Nov 2013

Nano-material within cells could lead to engineered bio-composites for drug delivery, artificial tissue

New York-A team of researchers has uncovered critical information that could help scientists understand how protein polymers interact with other self-assembling biopolymers.

22 Nov 2013